The Treasury Department is proposing rules to add biotechnology to its Outbound Investment Security Program under the COINS Act.
News|Videos|October 23, 2026
Every AI Agent Will Eventually Fail: Why Healthcare Leaders Need Supervision, Not Hope
Author(s)Authenticx
AI agents are moving into healthcare faster than most organizations can supervise them. In this conversation, Amy Brown, CEO of Authenticx, argues that every AI agent will eventually fail—and that the real differentiator isn't which company deploys AI first, but which one can see, catch, and correct what its AI is doing before a patient or member is harmed.
Learning Objectives:
- Learn why “every AI agent will fail” isn't a scare tactic—it's the reality of deploying probabilistic systems in high-stakes healthcare conversations.
- Understand what “supervision” actually means, and why it's different from dashboards, spot-checks, or a one-time launch checklist.
- Learn how healthcare leaders can build the continuous oversight needed to catch problems early—before they become patient safety or compliance risks.
Related to this article
Deborah Waterhouse is leaving ViiV Healthcare to become CEO and managing director of CSL.
METiS TechBio enters a collaboration with Eli Lilly to develop next-generation, tissue-specific lipid nanoparticle delivery technologies using METiS’s AI-driven lipid discovery platform.
AI does not end uncertainty in pharma strategy. Its value depends on how well leaders blend it with experience and evidence while keeping judgment human.
PaxSafe's Mark Talens on why pharma supply chain AI fails before it starts — and the data foundry framework that changes that.
Thomas Appio has been named interim CEO of Bausch + Lomb, a move coinciding with an expected upward revision to the company’s full-year guidance.
Trending on PharmExec
1
FDA Approves Hibsago (Bepirovirsen) for Chronic Hepatitis B
2
FDA Grants Ultomiris Accelerated Approval in the U.S. for Adults with Primary Immunoglobulin A Nephropathy
3
Roundup: Alcon Acquires Neurotech and Encelto, Ai Proteins Enters Research Collaboration and License Agreement with Astellas Pharma
4
Pharmaceutical Executive Daily: FDA Grants Ultomiris Accelerated Approval in the U.S.
5